about
Colorectal cancer: Metastases to a single organPersonalized treatment for advanced colorectal cancer: KRAS and beyondThe role of biological therapy in metastatic colorectal cancer after first-line treatment: a meta-analysis of randomised trialsMeta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancerMeta-analysis comparing the efficacy of anti-EGFR monoclonal antibody therapy between KRAS G13D and other KRAS mutant metastatic colorectal cancer tumours.Returning to work following curative chemotherapy: a qualitative study of return to work barriers and preferences for intervention.Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III).Sociodemographic disparities in survival from colorectal cancer in South Australia: a population-wide data linkage study.Breast cancer screening-opportunistic use of registry and linked screening data for local evaluation.Does the Chemotherapy Backbone Impact on the Efficacy of Targeted Agents in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis of the Literature.Targeted therapy for esophagogastric cancers: a reviewAssociation of BMI with overall survival in patients with mCRC who received chemotherapy versus EGFR and VEGF-targeted therapiesEpiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancer.Very high GFR in cancer patients undergoing chemotherapy: prevalence, carboplatin dosing patterns and chemotherapy toxicity.Cetuximab in metastatic colorectal cancer.Overview of biomarkers in metastatic colorectal cancer: tumour, blood and patient-related factors.Current opinion on optimal treatment for colorectal cancer.The effect of the UGT1A1*28 allele on survival after irinotecan-based chemotherapy: a collaborative meta-analysis.Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials.Current opinion on optimal systemic treatment for metastatic colorectal cancer: outcome of the ACTG/AGITG expert meeting ECCO 2013.Incorporating traditional and emerging biomarkers in the clinical management of metastatic colorectal cancer.RAS Mutations as Predictive Biomarkers in Clinical Management of Metastatic Colorectal Cancer.Update on optimal treatment for metastatic colorectal cancer from the ACTG/AGITG expert meeting: ECCO 2015.Use of guideline-recommended adjuvant therapies and survival outcomes for people with colorectal cancer at tertiary referral hospitals in South Australia.Goserelin toxicities and preferences for ovarian suppression method in pre-menopausal women with breast cancer.Pre-treatment serum lactate dehydrogenase as a biomarker in small cell lung cancer.Assessing impact of organised breast screening across small residential areas-development and internal validation of a prediction model.Pregnancy screening prior to chemotherapy administration.Perceptions of cancer of unknown primary site: a national survey of Australian medical oncologists.Germline polymorphisms as biomarkers of tumor response in colorectal cancer patients treated with anti-EGFR monoclonal antibodies: a systematic review and meta-analysis.Australian recommendations for EGFR T790M testing in advanced non-small cell lung cancer.Colorectal cancer treatment and survival over three decades at four major public hospitals in South Australia: trends by age and in the elderly.Is Survival for Patients with Resectable Lung Metastatic Colorectal Cancer Comparable to Those with Resectable Liver Disease? Results from the South Australian Metastatic Colorectal Registry.Survival improvements associated with access to biological agents: Results from the South Australian (SA) metastatic colorectal cancer (mCRC) registry.Phase II study of celecoxib with docetaxel chemoradiotherapy followed by consolidation chemotherapy docetaxel plus cisplatin with maintenance celecoxib in inoperable stage III nonsmall cell lung cancer.Comorbidity, age and overall survival in cetuximab-treated patients with advanced colorectal cancer (ACRC)--results from NCIC CTG CO.17: a phase III trial of cetuximab versus best supportive care.Metastatic Colorectal Cancer in Young Adults: A Study From the South Australian Population-Based Registry.Metastatic Colorectal Cancer Treatment and Survival: the Experience of Major Public Hospitals in South Australia Over Three Decades.Usefulness of Aquaporin 1 as a Prognostic Marker in a Prospective Cohort of Malignant Mesotheliomas.Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17.
P50
Q26778009-835CE50B-F11A-4673-AAB6-F86DB88AAAD5Q26822817-F33404BE-FF79-4AA9-8AB8-C7E4D0D65A7CQ26858892-B5559329-A6F3-4C79-9D67-F689DC40684BQ27027648-901A4A70-1670-458F-9597-01D7E891BB52Q27853329-AB8724E8-E188-47D9-ABB0-8EEA1EC90388Q30209236-41C433E5-B130-436B-997A-064B65B77B35Q30317994-9B49B729-68E9-4E53-8C0B-96BB33430949Q31038597-EDE0BD07-C64E-46D0-9462-1366ADAA065AQ31132263-C46C6373-0982-4774-9DB0-A9AFFEE9EE2DQ35746635-740746C5-8543-4620-8F5C-42C4EC8A4661Q36039645-D6E675E1-91B9-4878-BD64-32B6647B8C91Q36201447-ED32261F-AD54-4CFE-935D-F884B8426F90Q37558996-8ADC09BB-BAB7-48F5-8B44-BC5B347AB6F5Q37925135-9656C669-DD57-4EDE-A3FB-55A63D5192A4Q38010796-5A71A392-D232-44E1-9ABF-B1409BC91AB7Q38023976-7B22F9D8-60B0-4154-B8E4-90DF513DAABEQ38101612-244822B9-5326-4C1B-8437-9740CA9586B5Q38202816-6FA39A81-E97C-49FA-B351-E60FA62BDF67Q38239192-948D5FD7-6AEC-4FB3-B903-0EBDF86FC7AFQ38241395-1880F034-F148-47A2-8BCC-F7F1544074D3Q38545768-3E661863-BDE1-4C40-A497-8BB6123DA51FQ38764778-1BEBED58-8CDA-408D-8AA3-FDAD6BB280BEQ38787278-39478824-D080-45D3-8871-9C77E757270FQ38802762-D67D2376-0B21-42F3-A2F6-FE25AED4774BQ38844210-A2696A92-7862-41DA-80EE-B30B29217628Q38919028-BBE26236-F17A-4F92-88DC-F413516F3E44Q38921745-EFD677F7-EBBA-47E3-A376-9B42D6773BDBQ38979380-0AF56ED8-27F1-446C-B93C-8038D15D09B4Q39013175-B7F7F144-FCF8-41AC-8F43-19394302BC62Q39023377-A71D304A-1BC4-4CF2-8451-DB7FB74701D0Q39430016-147C65D7-CE2E-4689-9FB2-C3D51819A994Q39714343-D2AADD82-98CB-494B-B701-30A3956FEBBDQ39717499-DC8C1D61-4822-40B6-AAE4-123B9E990EB1Q39996371-FE6FC6CC-4A1E-486D-9C45-8592CA1A3086Q40079747-279420A6-505B-4936-A1AD-2DCE9BDCDBDCQ40354587-0202DBAF-5AF6-4A11-B404-782E010B0C94Q40572062-3083C906-409D-4E10-B65C-5D675CC2EEE0Q40593332-AA087B1D-F40A-4B3C-B3F4-029FC2A474DAQ40668409-91D1AC9A-B60E-4BF7-98C0-7A344CABC410Q40933980-E2408B8D-7416-4035-B783-B4C709B93AE7
P50
description
investigador
@es
researcher
@en
name
Christos S Karapetis
@en
type
label
Christos S Karapetis
@en
prefLabel
Christos S Karapetis
@en
P31
P496
0000-0003-1741-996X